detemir insulin + aspart insulin + metformin

This drug is a combination therapy comprising **insulin detemir** (a long-acting insulin analogue), **insulin aspart** (a rapid-acting insulin analogue), and **metformin** (an oral biguanide antihyperglycemic agent). The combination is used in the treatment of **type 2 diabetes mellitus** to improve glycemic control. Insulin detemir provides basal insulin coverage through slow systemic absorption and prolonged distribution due to high serum albumin binding; insulin aspart provides rapid prandial glucose control by quickly stimulating peripheral glucose uptake; metformin decreases hepatic glucose production and improves insulin sensitivity. Together, this regimen targets both fasting and postprandial glucose, improves insulin function, and reduces insulin resistance. Recent clinical trials demonstrate that this triple therapy significantly improves glycemic indices, insulin function, quality of life, and sleep quality in newly diagnosed type 2 diabetes patients compared to dual therapy[1][3][5][6].